Short Interest in Calidi Biotherapeutics, Inc. (NYSEAMERICAN:CLDI) Expands By 859.7%

Calidi Biotherapeutics, Inc. (NYSEAMERICAN:CLDI) was the target of a large growth in short interest during the month of April. As of April 15th, there was short interest totalling 1,430,000 shares, a growth of 859.7% from the March 31st total of 149,000 shares. Based on an average trading volume of 632,000 shares, the short-interest ratio is currently 2.3 days.

Calidi Biotherapeutics Trading Up 1.3 %

Shares of CLDI traded up $0.00 during trading hours on Thursday, hitting $0.16. The stock had a trading volume of 533,100 shares, compared to its average volume of 532,412. Calidi Biotherapeutics has a fifty-two week low of $0.14 and a fifty-two week high of $13.79.

Wall Street Analysts Forecast Growth

Several research firms have recently commented on CLDI. HC Wainwright dropped their price objective on shares of Calidi Biotherapeutics from $11.00 to $2.00 and set a “buy” rating on the stock in a report on Thursday, March 21st. Robert W. Baird dropped their price objective on shares of Calidi Biotherapeutics from $9.00 to $4.50 and set an “outperform” rating on the stock in a report on Thursday, March 21st.

Hedge Funds Weigh In On Calidi Biotherapeutics

A hedge fund recently bought a new stake in Calidi Biotherapeutics stock. Spectrum Asset Management Inc. NB CA bought a new stake in Calidi Biotherapeutics, Inc. (NYSEAMERICAN:CLDI) in the 1st quarter, according to its most recent filing with the SEC. The fund bought 166,494 shares of the company’s stock, valued at approximately $94,000. Spectrum Asset Management Inc. NB CA owned 0.47% of Calidi Biotherapeutics at the end of the most recent reporting period. Institutional investors own 12.53% of the company’s stock.

About Calidi Biotherapeutics

Calidi Biotherapeutics, Inc, a clinical stage immuno-oncology company, engages in developing allogeneic stem cell-based platforms to potentiate and deliver oncolytic viruses to cancer patients in the United States. Its product pipeline comprising CLD-101, which is in phase 1b clinical trial for the treatment of high grade glioma; CLD-101, which is in phase 1 clinical trial for the treatment of recurrent high grade glioma; CLD-201, which is in preclinical trial for the treatment of advanced solid tumors, such as triple-negative breast cancer, metastatic/unresectable melanoma, head and neck squamous cell carcinoma, advanced soft tissue sarcoma, and advanced basal cell carcinoma; and CLD-400, which is in preclinical trial for the treatment of lung cancer and metastatic solid tumors.